Article of the Week, Suggested by the BPDCN International Registry
Immune Oncology Research Institute shared a post on LinkedIn:
“Article of the Week Suggested by the BPDCN International Registry – Astghik Voskanyan
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia primarily affecting older men, with involvement often in the skin, bone marrow, lymph nodes, and CNS. Due to its rarity and unique management needs, patients should ideally be referred to specialized cancer centers with clinical trials and expertise in BPDCN. Comprehensive staging and expert hematopathology review are essential. BPDCN universally expresses CD123, the IL-3 rec..eptor, a key therapeutic target. Treatment options include tagraxofusp, a CD123-targeting IL3-diphtheria toxin conjugate, or conventional chemotherapy. Allogeneic hashtag#HSCT in first remission (CR1) is recommended if feasible. Treatment choice depends on disease features, patient health, goals, and available center expertise. Close monitoring for toxicities, especially capillary leak syndrome (CLS), is crucial when using tagraxofusp, particularly in the first cycle.
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
Authors: Marlise R. Luskin, Andrew A. Lane
Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.
Other posts featuring Immune Oncology Research Institute on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023